ReviewJournal of blood medicine2019
Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
Review in Journal of blood medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04949009 (Avatrombopag in the Treatment of Primary Immune Thrombocytopenia), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP): a Single-arm, Multi-centre, Observational Study
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.Annals of medicine · 2023Trial
- Avatrombopag switching from other thrombopoietic agents in severe and persistent cancer treatment-induced thrombocytopenia: a multicentre real-world study.Frontiers in medicine · 2026Article
- Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?Research and practice in thrombosis and haemostasis · 2025Article
- Avatrombopag for the Treatment of Immune Thrombocytopenia.European journal of haematology · 2025Review
- Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers.Gynecologic oncology reports · 2024Article
- Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation.Annals of hematology · 2024Review
- Avatrombopag for adults with early versus chronic immune thrombocytopenia.American journal of hematology · 2024Observational
- Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.Blood reviews · 2024Review
- Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.BMC cancer · 2023Article
- Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.Expert review of hematology · 2023Review
- Small Molecule Drugs That Inhibit Phagocytosis.Molecules (Basel, Switzerland) · 2023Article
- Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.British journal of haematology · 2022Observational
- Dualistic role of platelets in living donor liver transplantation: Are they harmful?World journal of gastroenterology · 2022Review
- Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use.Research and practice in thrombosis and haemostasis · 2022Article
- Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial.Frontiers in pharmacology · 2022Article
- [Chinese expert consensus on the management of hemorrhagic complications after hematopoietic stem cell transplantation(2021)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Emerging Therapies in Immune Thrombocytopenia.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avatrombopag is an orally-administered small molecule thrombopoietin receptor agonist. It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Unlike eltrombopag, avatrombopag does not require a 4 hr food-restricted window around its use and it has not been associated with hepatotoxicity in ITP patients or portal vein thrombosis in patients with chronic liver disease. In ITP patients it can often be dosed less frequently than once daily. It is overall well-tolerated with a side-effect profile similar to placebo in randomized clinical trials. This article will review the clinical development, efficacy, safety, and pharmacology of avatrombopag for use in patients with ITP and thrombocytopenia of chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.